Last reviewed · How we verify
induction with aromataze inhibitor
The drug, an aromatase inhibitor, is currently marketed by Minia University, positioning it in a competitive landscape of hormonal therapies. A key strength lies in its patent protection, which is secured until 2028, providing a period of exclusivity. The primary risk is the lack of disclosed revenue data, which may indicate limited market penetration or sales performance.
At a glance
| Generic name | induction with aromataze inhibitor |
|---|---|
| Also known as | letrozole |
| Sponsor | Minia University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome (PHASE3)
- Role of Aromatase Inhibitor to Enhance Ovulation in Poor Responder During Induction With Short Antagonist Protocol in Cases of ICSI (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- induction with aromataze inhibitor CI brief — competitive landscape report
- induction with aromataze inhibitor updates RSS · CI watch RSS
- Minia University portfolio CI